What Supralip Treats: Main Uses and Benefits

Supralip (fenofibrate) is applied in addressing conditions involving fatty substances (lipids) in the blood. It is primarily used as an adjunct to diet and other non-pharmacological treatments to help manage these lipids, and is relevant for managing symptoms related to systemic imbalance. This treatment is used for managing certain fatty substances, supporting patients when acute or fluctuating manifestations create discomfort or instability. It is commonly used to help with the overall symptom load.

Supportive Benefit Focus

The medicine is commonly used across conditions characterized by episodic or fluctuating manifestations where symptoms related to systemic imbalance lead to discomfort. It helps address symptom clusters that may become intense or disruptive. When symptoms are noticeable, the medication supports general well-being during symptomatic phases. It may assist with easing the overall symptom load.

---

Quick Fact: Relevant for Symptom Domains Supralip may be part of symptomatic management applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Supralip?

Supralip (fenofibrate) eligibility is strictly defined by regulatory authorities and is primarily established for the adult population (18 years and older).

Contraindications: Populations Who Must Not Use Supralip

Official labeling mandates that Supralip is contraindicated in specific populations and conditions. You must not use this medicine if any of the following applies:

Contraindicated Factor	Specific Condition
Organ Function	Active liver disease (including unexplained persistent abnormal liver function) or severe renal impairment (estimated GFR < 30 mL/min/1.73m^2).
Age	Pediatric patients (children and adolescents under 18 years of age), as safety and efficacy are not established.
Disease History	Known hypersensitivity to fenofibrate, pre-existing gallbladder disease, chronic or acute pancreatitis, or a history of photoallergy to fibrates.

Restricted and Special-Consideration Use

Use is officially not recommended in several other circumstances. This includes individuals with moderate renal impairment (GFR 30–59 mL/min/1.73m^2). Furthermore, the medicine is not recommended for women who are pregnant or breastfeeding due to insufficient safety data for these groups. Older adults may use Supralip but require careful monitoring, particularly of renal function.

Interaction Map: Interactions with other medicines and products — official regulatory information for Supralip

Interaction Scope

Element	Official Regulatory Information
Medicinal product categories with documented interactions	HMG-CoA Reductase Inhibitors (Statins), Coumarin Anticoagulants, Immunosuppressants, Bile Acid Resins, Colchicine.
Timing-based interaction rules (if applicable)	Must be administered at least 1 hour before or 4 to 6 hours after a Bile Acid Resin (e.g., Cholestyramine).
Population-specific interaction notes (if applicable)	Increased risk of myopathy is heightened in the elderly and patients with diabetes, renal failure, or hypothyroidism.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification	Clinically Significant Interactions (Warfarin, Statins, Colchicine).
Interaction-context constraints	Certain formulations require administration with food to ensure official drug absorption. Alcohol may worsen the underlying hypertriglyceridemia.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with HMG-CoA Reductase Inhibitors (Statins) and Colchicine is associated with an increased pharmacodynamic risk of myopathy and rhabdomyolysis.
• The anticoagulant effect of Coumarin Anticoagulants is potentiated, leading to prolongation of the Prothrombin Time/INR, which necessitates a dosage reduction of the anticoagulant.
• Bile Acid Resins interfere with Fenofibrate absorption, requiring temporal separation in administration.
• Fenofibric acid is an in vitro inhibitor of CYP2C8, CYP2C19, CYP2A6, and CYP2C9; in vivo data shows altered exposure for certain co-administered substrates, such as Glimepiride and Atorvastatin.
• Co-administration with Immunosuppressants requires caution due to the potential for nephrotoxic effects.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure around pharmacodynamic risk reinforcement and pharmacokinetic modification. This framework establishes official constraints, including a mandatory monitoring requirement for Prothrombin Time and specific time separation rules to manage the known effects of co-administration on the drug's absorption and the risk profile of interacting agents.

The mechanism of Fenofibrate (Supralip) is defined by its ability to modulate the expression of genes involved in fat processing, achieved through a single, selective molecular target. The drug's active form, fenofibric acid, acts as a highly selective agonist for the nuclear receptor Peroxisome Proliferator-Activated Receptor alpha (PPARalpha). This binding initiates transcriptional regulation, directly adjusting the output of key genes that govern the body's synthesis and breakdown of lipids.

Activation of PPARalpha creates a dual mechanism for clearing fats: it both enhances catabolism and reduces production. It upregulates Lipoprotein Lipase (LPL) activity while simultaneously downregulating Apolipoprotein C-III (Apo C-III), the inhibitor of LPL. This coordinated effect leads to a reduction in circulating triglycerides and VLDL particles.

Fenofibrate's mechanism also increases the synthesis of Apolipoprotein A-I (Apo A-I), a key structural component of High-Density Lipoprotein (HDL-C). This results in an increase in HDL-C levels, which facilitates the reverse transport of cholesterol. Furthermore, the overall reduction in circulating triglycerides modifies the composition of LDL particles, resulting in a shift toward larger, more buoyant forms.

Instruction Map: How to use Supralip — official administration guidelines

Administration scope

Route of administration:

• Oral use only.

Dosing schedule:

• The drug is administered as a single dose once daily. For Primary Hyperlipidemia or Mixed Dyslipidemia, the usual dose is typically 130 mg to 160 mg once daily, depending on the specific formulation being used. Dosage is individualized and subject to adjustment following lipid determinations.

Timing in relation to meals (if applicable):

• This varies by product formulation; some fenofibrate products can be taken with or without food, while others must be taken with a meal to ensure proper absorption.

Preparation requirements (if applicable):

• Tablets and capsules must be swallowed whole; they must not be crushed, broken, dissolved, or chewed.

Age-group administration rules:

• Use is not recommended for the pediatric population (under 18) as safety and efficacy have not been established.
• Dosage for geriatric patients is determined based on an assessment of renal function.

Missed-dose rules:

• Do not take an extra dose to compensate for the missed one; resume treatment with the next regularly scheduled dose.

Special procedural conditions:

• Patients with mild to moderate renal impairment must start on a lower initial dose (e.g., 43 mg or 48 mg once daily).
• When co-administered with a bile acid binding resin, fenofibrate must be taken at least 1 hour before or 4 to 6 hours after the resin.

---

Instruction classifications (high-level)

Administration method type: Oral

Frequency pattern: Daily (once per day)

Regulatory basis: Standardized clinical guidelines for core usage structure.

Use-context constraints: Mandatory dietary adherence, renal function dependency for dosing, food dependency for certain formulations, and specific time separation from bile acid binding resins.

---

Resulting procedural structure

Official step sequence:

• Initiate treatment while continuing an appropriate lipid-lowering diet.
• Select the starting dose based on formulation and patient renal status.
• Administer the medication once daily, ensuring it is taken whole and according to the specific food requirement.
• Perform repeat lipid determinations and adjust dosage at intervals of 4 to 8 weeks.
• Discontinue treatment if an adequate lipid response is not achieved after two to three months at the maximum recommended dose.

Connection to the overall use protocol (2–4 sentences): The official instructions structure the use of fenofibrate as a long-term, titrated regimen that requires initial dose setting based on physiological status and formulation choice. This process mandates periodic clinical monitoring for response and necessary dose adjustments over time. The instructions strictly define the oral administration technique and food-timing rules to optimize product intake and ensure proper absorption.

Research Evidence / Overview of Studies for Supralip (Fenofibrate)

---

Evidence for Use in Managing Severe Hypertriglyceridemia

Research has explored the use of the active component in Supralip, fenofibrate, in adults presenting with highly elevated triglyceride levels in the blood. These studies were primarily short-term randomized controlled trials (RCTs) that looked at how circulating fat levels change over defined time intervals. Studies reported measurements showing a measurable change in triglyceride levels across the observed short-term follow-up periods. What remains unclear is the relationship between the observed short-term biomarker change and long-term clinical outcomes over many years. There is limited information for long-term outcomes specifically evaluating how the management of these high levels relates to the prevention of major, acute complications.

---

Evidence for Use in Primary Hypercholesterolemia and Mixed Dyslipidemia

For the broader use in managing imbalances involving both high cholesterol and high triglycerides (known as mixed dyslipidemia), research has involved large, long-term randomized controlled trials as well as systematic reviews. These studies often included high-risk adults, particularly those with co-existing Type 2 Diabetes. Studies explored how changes in lipid biomarkers like LDL-C, HDL-C, and triglycerides related to clinical outcomes, such as major adverse cardiovascular events (heart attack, stroke, or CV death), that were the focus of measurement. The large, long-term trials reported that the medicine did not report a statistically significant difference in the overall primary clinical outcomes when administered to the broad population of high-risk patients. Findings were mixed, and the certainty remains low regarding a generalized clinical finding for reducing major cardiovascular events.

---

Studies on Microvascular Complications in Diabetic Populations

Research has explored the role of fenofibrate in studies observing long-term complications associated with Type 2 Diabetes, such as diabetic retinopathy (eye damage). These studies involved major, long-term randomized controlled trials that specifically monitored changes in the eye. The studies reported how symptoms evolved in the observed populations with Type 2 Diabetes. The findings described patterns that suggested a pattern of difference in the progression of the eye condition, such as the need for laser treatment. Findings primarily involve studies of patients with Type 2 Diabetes and long-term outcomes of the medicine are not fully established outside of this population.

---

What is Still Uncertain about Supralip Research

The evidence highlights what is known, and what is still uncertain, about this medicine. A primary limitation is the inconsistency of findings regarding the overall reduction of major cardiovascular events in broad, high-risk populations. The long-term outcomes of the medicine are not fully established outside of the measured biomarker shifts. The generalizability of findings from certain subgroup analyses remains an area of ongoing research and debate. Follow-up durations were limited for certain outcomes, and comparative evidence is lacking against newer lipid-modifying treatments. Certainty remains low regarding the extrapolation of observed patterns to patients who do not fit the exact profile of those included in the major clinical trials.

Key Studies & References

1. Cardiovascular disease: risk assessment and reduction, including lipid modification (NICE Guideline CG181)

Common questions about Supralip (FAQ)

---

Q: Is Supralip a statin or a different type of medication?

Supralip’s active ingredient, fenofibrate, is classified in official sources as a fibrate or fibric acid derivative. This places it in a different class of lipid-modifying agents than statins (HMG-CoA reductase inhibitors). Official information indicates these two classes work through distinct mechanisms to manage blood fat levels.

---

Q: Is Supralip used for high triglycerides?

Yes, official regulatory indications describe the medicine for treating severe hypertriglyceridemia, which means highly elevated levels of triglycerides (a type of fat) in the blood. Its use is intended to be combined with diet changes to help manage these high fat levels.

---

Q: Can Supralip cause muscle aches or leg pain?

Regulatory safety documents list muscle disorders, such as myalgia (muscle pain or aches), as an uncommon adverse reaction. Official information indicates that, in rare instances, more serious muscle issues are possible, which is why periodic monitoring of muscle-related lab values may be required during treatment.

---

Q: Is Supralip known to cause problems with the liver?

Official safety documents indicate that an increase in liver transaminases (certain lab values) is a common reported reaction. Due to the potential for liver effects, the medicine is formally contraindicated (must not be used) in patients who have active liver disease. Regular monitoring of liver function tests is a required part of official guidance.

---

Q: Can I take Supralip if I have kidney issues?

The official product information specifies that Supralip is contraindicated if you have severe renal (kidney) impairment. For individuals with mild or moderate renal impairment, official guidelines indicate that dosage is determined based on an assessment of renal function, and monitoring is a mandatory part of therapy.

---

Q: Are there any known interactions between Supralip and common pain relievers?

The official interaction profile documents a recognized interaction with the medicinal product Colchicine, which is used for inflammatory conditions like gout. However, official drug labels do not typically list or exclude every common over-the-counter pain reliever.

---

Q: Can Supralip affect how blood thinner medications work?

Yes, regulatory documents describe that when Supralip is used alongside Coumarin anticoagulants (a type of blood thinner), it can intensify the anticoagulant effect. Because of this, the official interaction management guidelines include a mandatory monitoring requirement for Prothrombin Time/INR during co-administration.

---

Q: Why do doctors prescribe Supralip for people who already take cholesterol medicine?

Official indications describe the product as an adjunct, meaning an addition, to diet and other non-medicinal therapies. It may be prescribed when primary cholesterol-lowering medicines (like statins) are already being used, but there is still a need for significant management of high triglycerides or further modification of the overall cholesterol profile.

---

Q: Does the use of alcohol affect Supralip?

Official warnings note that excessive consumption of alcohol is considered a risk factor for worsening the underlying condition of hypertriglyceridemia (high blood fats). The medicine’s effectiveness relies on an overall lipid-lowering plan that includes diet.

---

Q: Does taking Supralip make you feel tired or fatigued?

The official side effect lists do not specifically include the general feeling of tiredness or fatigue. However, they do list other reactions that could potentially affect energy, such as headache (common) and asthenia (a medical term for weakness or lack of energy), which is listed as uncommon.

---

Q: Is Supralip more effective for triglycerides or for LDL ('bad') cholesterol?

Official clinical and mechanism documents describe a primary action of reducing circulating triglycerides and a related type of fat particle called VLDL. While it also modifies the composition of LDL and increases HDL-C ('good' cholesterol), its formal use includes the treatment of severe hypertriglyceridemia, indicating a key role in managing high fat levels.

---

Q: Why is Supralip sometimes prescribed with other medicines?

Regulatory documents state that Supralip is indicated as an adjunct to diet and non-medicinal therapies. This means it is designed to be part of a comprehensive management strategy, often used in combination with other treatments for high blood fat levels.

---

Q: How long does it typically take to see changes in lab results after starting Supralip?

Official administration instructions define the time window for checking lab results and making dose adjustments as 4 to 8 weeks after starting. This suggests that a measurable therapeutic response sufficient for clinical evaluation is expected within this initial timeframe.

---

Q: Are there any food or drinks I should avoid while taking Supralip?

The administration rules for certain formulations require that the medicine be taken with a meal to ensure it is properly absorbed by the body. Furthermore, official warnings note that excessive alcohol use may be detrimental to the underlying condition being treated.

---

Q: Is Supralip safe to use long-term?

The official step sequence describes a long-term, titrated regimen. The medicine is intended for chronic use if an adequate response is achieved. The duration of treatment is determined by the patient’s response and clinical assessment over time.

---

Q: Does taking Supralip affect blood sugar levels?

Clinical studies have examined the medicine in high-risk adult populations, particularly those with co-existing Type 2 Diabetes. While its use in this population is noted, the regulatory label does not make a general claim about the medicine’s overall effect on blood sugar levels in people without diabetes.

---

Q: Is Supralip available over the counter in any country?

Regulatory documents consistently classify the active ingredient, fenofibrate, as a prescription-only medicine in the regions where major health authorities operate. A prescription from a licensed healthcare provider is required to obtain this medicine.

---

Q: Is it normal to feel a little nauseous when starting Supralip?

Nausea is listed as a common adverse reaction in the official safety profile. Common reactions are defined as those that may affect up to 1 in 10 people, meaning it is a frequently reported experience, especially when first starting treatment.

---

Q: Does Supralip have to be taken at a specific time of day?

Official administration instructions mandate taking a single dose once daily. While certain formulations must be taken with a meal for proper absorption, regulatory documents do not specify a fixed time of day, such as morning or evening.

---

Q: What is the difference between Supralip and common statin medications?

Supralip is a fibrate, which primarily works by activating a molecular receptor (PPAR alpha) to increase the body's breakdown of fats. Statins work differently by blocking an enzyme involved in the production of cholesterol. They target different parts of fat and cholesterol metabolism.

---

Q: Are there any gender-specific concerns with taking Supralip?

Regulatory documents focus on specific use restrictions for women regarding reproduction. The medicine is not recommended during pregnancy or breastfeeding due to insufficient safety data for these groups. General gender-specific concerns outside of this context are not officially documented.

---

Q: Is Supralip generally considered appropriate for elderly patients?

Official documents state that older adults may use the medicine, but this population requires careful monitoring, particularly of renal function (kidneys). The risk of serious muscle damage is also officially documented as being increased in the elderly population.

---

Q: What are the official regulatory approvals for Supralip?

The active ingredient, fenofibrate, is formally approved as an adjunct to diet for conditions including primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. These are the specific conditions for which health authorities have granted approval.

---

Q: What should I do if I miss a dose of Supralip?

The official missed-dose rule is that you should not take an extra dose to try and make up for the missed one. Instead, you should simply resume your treatment by taking the next regularly scheduled dose.

---

Q: What is the typical duration of treatment with Supralip?

The official instructions describe the use as a long-term, titrated regimen intended to be continued for an extended period, provided a positive therapeutic response is confirmed by lab tests. If an adequate lipid response is not achieved after two to three months at the maximum recommended dose, official guidance recommends discontinuing the medicine.

---

Q: What are the serious side effects that require medical attention?

Official documents describe several Serious Adverse Reactions that are considered clinically significant risks. These include serious muscle breakdown (Rhabdomyolysis), Serious Drug-Induced Liver Injury, and acute Hypersensitivity Reactions such as anaphylaxis and angioedema. These conditions are officially noted in the safety warnings.

---

Q: Does Supralip have a generic name?

Yes, the active ingredient in the medicine is Fenofibrate, which is the generic name. The medicine may be available under different brand names, depending on the country or manufacturer.

---

Q: Is Supralip available in different strengths?

Official regulatory documents confirm that the active ingredient is available in different strengths, such as 43 mg, 48 mg, 130 mg, 145 mg, and 160 mg, across various approved formulations and dosing protocols.

--UNSAFE

Q: What is the mechanism by which Supralip affects fat levels in the blood?

The active ingredient operates by activating a protein in the body called PPAR alpha. This activation initiates a regulatory process that helps the body process fats, leading to both an increased breakdown and removal of fat particles and a reduced production of those particles in the blood.

---

Q: Do I need to change my diet while taking Supralip?

Official documents define the use of this medicine as an adjunct to diet. This means its use is initiated and maintained in the context of continuing an appropriate lipid-lowering diet.

---

Q: How does Supralip work to reduce cardiovascular risk?

Research has explored the medicine’s role in high-risk populations. Official evidence documents indicate that large, long-term trials did not report a statistically significant difference in overall primary clinical outcomes for the broad population of high-risk patients. The certainty regarding a generalized cardiovascular benefit remains low.

---

Q: Are there different brand names for the active ingredient in Supralip?

Yes, the generic active ingredient, fenofibrate, is available under multiple different brand names in various regions and markets around the world.

---

Q: What is the expected outcome of taking Supralip?

The product is expected to achieve a measurable therapeutic effect by reducing circulating triglycerides and VLDL particles and causing an increase in HDL-C levels. Official documents note that while this changes biomarkers, there is uncertainty regarding its overall effect on reducing major cardiovascular events in broad populations.

---

Q: Is it possible to be allergic to Supralip?

Yes, the medicine is formally contraindicated (must not be used) in patients who have a known hypersensitivity or allergy to fenofibrate or a history of allergic reactions (like photoallergy) to similar fibrate drugs.

---

Q: What is the scientific classification of the drug Supralip?

The active component of Supralip is scientifically classified as a fibric acid derivative. This places it within the broader pharmacological class of lipid-modifying agents (or fibrates) used to manage blood fat levels.

---

Q: Is there a maximum time someone can take Supralip?

The treatment is intended for long-term use, provided a patient shows an adequate response. While there is no defined maximum duration, official guidance requires discontinuation if an adequate lipid response is not achieved after two to three months at the maximum dose prescribed.

Storage and Disposal of Supralip (Fenofibrate)

Official labeling defines specific conditions for storing Supralip tablets to maintain their quality and efficacy.

---

Storage Requirements

• Temperature and Moisture: Store the medicine at a temperature not exceeding 30 C and protect from moisture.
• Container Rules: The tablets must be kept in the original package.
• Handling Restrictions: The product must not be frozen.
• Child Safety: Always keep this medicine out of the sight and reach of children.

---

Disposal

Disposal of unused or expired Supralip must be carried out in accordance with local requirements. Do not dispose of the medicine via household wastewater or general trash unless advised by a pharmacist or a formal drug take-back program.